More recently, a reanalysis of three large random- ized trials (Treating to New Targets, TNT; Incremental Decrease in End- points through Aggressive Lipid Lowering, IDEAL; Stroke Prevention by Aggressive Reduction in Cholesterol Levels, SPARCL) was focused on the incidence of new-onset T2DM, an end-point that was not originally in- cluded in these trials [34].
เมื่อเร็วๆนี้